Recordati
Global pharmaceutical group operating across research & development, active pharmaceutical ingredient (API) production, finished-dose manufacturing, commercialization and licensing. Active in specialty, primary care and rare diseases with a presence in approximately 150 countries, multiple manufacturing sites and chemical plants. Publishes regulatory transparency reports and maintains structured sustainability and compliance programs.
Industries
Nr. of Employees
Very Large (1000+)
Products
Medicines for specialty, primary care and rare diseases
Portfolio of marketed therapies across general medicine, specialty care and rare disease indications.
Active pharmaceutical ingredients (APIs)
In-house and contract-produced APIs supplied to pharmaceutical customers worldwide.
LERCAPRESS 20 mg/10 mg, comprimé pelliculé
Enalapril maleate and lercanidipine hydrochloride film-coated tablet.
ZANEXTRA 20 mg/20 mg, comprimé pelliculé
Enalapril maleate and lercanidipine hydrochloride film-coated tablet.
SYLVANT 100mg -Turkey
Sylvant 100mg pharmaceutical product archived under rare disease category.
Sylvant 400 mg
Sylvant 400 mg is a pharmaceutical product provided by Recordati in Austria.
Medicines for specialty, primary care and rare diseases
Portfolio of marketed therapies across general medicine, specialty care and rare disease indications.
Active pharmaceutical ingredients (APIs)
In-house and contract-produced APIs supplied to pharmaceutical customers worldwide.
LERCAPRESS 20 mg/10 mg, comprimé pelliculé
Enalapril maleate and lercanidipine hydrochloride film-coated tablet.
ZANEXTRA 20 mg/20 mg, comprimé pelliculé
Enalapril maleate and lercanidipine hydrochloride film-coated tablet.
SYLVANT 100mg -Turkey
Sylvant 100mg pharmaceutical product archived under rare disease category.
Sylvant 400 mg
Sylvant 400 mg is a pharmaceutical product provided by Recordati in Austria.
Services
Development and contract synthesis services for active pharmaceutical ingredients, supporting early-stage development through industrial production.
Manufacture and supply of finished-dose pharmaceutical products for commercial markets.
Preparation and publication of transfer-of-value disclosures and support for compliance with industry codes and national regulations.
Operational support for clinical studies including execution of Phase II studies and indication extension programs.
Safety reporting systems and medical information contacts for adverse event reporting and product inquiries.
Programs to support patient access to therapies (patient assistance, co-pay programs) and educational initiatives for rare disease communities.
Development and contract synthesis services for active pharmaceutical ingredients, supporting early-stage development through industrial production.
Manufacture and supply of finished-dose pharmaceutical products for commercial markets.
Preparation and publication of transfer-of-value disclosures and support for compliance with industry codes and national regulations.
Operational support for clinical studies including execution of Phase II studies and indication extension programs.
Safety reporting systems and medical information contacts for adverse event reporting and product inquiries.
Programs to support patient access to therapies (patient assistance, co-pay programs) and educational initiatives for rare disease communities.
Expertise Areas
- API development and contract manufacturing
- Finished-dose formulation and commercial manufacturing
- Rare disease therapeutic development
- Clinical trial planning and execution
Key Technologies
- cGMP manufacturing
- Active pharmaceutical ingredient synthesis
- Finished-dosage production and formulation
- Laboratory Information Management Systems (LIMS)
News & Updates
Scheduled corporate and investor events including financial calendar meetings and conference calls.
Collection of administrator reports, meeting notices and proxy materials published in March–April 2024 for the Annual General Meeting.
Public archive of shareholder meeting notices, minutes, consolidated financial statements and non-financial declarations covering multiple years (historical records from at least 2010 onward).
Awarded EcoVadis Gold medal, placing the group among the top 5% of assessed companies.
MSCI ESG Research confirmed an A rating for the group in July 2025.
ISS ESG assigned a B- rating with 'Prime' status, indicating leading sustainability performance in the sector.
Scheduled corporate and investor events including financial calendar meetings and conference calls.
Collection of administrator reports, meeting notices and proxy materials published in March–April 2024 for the Annual General Meeting.
Public archive of shareholder meeting notices, minutes, consolidated financial statements and non-financial declarations covering multiple years (historical records from at least 2010 onward).
Awarded EcoVadis Gold medal, placing the group among the top 5% of assessed companies.
MSCI ESG Research confirmed an A rating for the group in July 2025.
ISS ESG assigned a B- rating with 'Prime' status, indicating leading sustainability performance in the sector.